Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK Belantamab...

    GSK Belantamab Mafodotin shows to help blood cancer patients

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-26T09:15:05+05:30  |  Updated On 13 Aug 2021 2:39 PM IST

    Two doses of Belantamab Mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said.


    New Delhi: GlaxoSmithKline said its experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business.


    Two doses of Belantamab Mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday, adding that it intends to seek market approval and submit data from the trial to regulatory bodies this year.


    Also Read: GSK: US pharma president Jack Bailey to step down in December


    GSK sold its approved oncology drugs to Novartis in 2014 but has staged a comeback bid in cancer with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement to pay up to 3.7 billion euros to Germany's Merck KGaA for the rights to next-generation immunotherapy in February.


    "We are on track to file Belantamab Mafodotin later this year and continue to investigate how it could help even more patients with this disease," Chief Scientific Officer Hal Barron said.


    Belantamab Mafodotin targets a protein linked to multiple myeloma known as BCMA.


    Also Read: GSK ends Ebola vaccine RnD; transfers license to US institute


    "This is yet another positive signal that GSK's R&D engine is being turned around and should be well received by the market," Liberum analyst Graham Doyle said.


    By Ludwig Burger and Pushkala Aripaka

    BCMABelantamabblood cancerdrugGlaxoSmithKlineGSKgsk drugimmunotherapyLudwig BurgerMafodotinMerckmyelomaNovartisoncology drugpharmapharma newsPushkala Aripaka
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok